Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.58
- Piotroski Score 3.00
- Grade Buy
- Symbol (KTTA)
- Company Pasithea Therapeutics Corp.
- Price $3.28
- Changes Percentage (4.13%)
- Change $0.13
- Day Low $2.92
- Day High $3.37
- Year High $17.40
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 12/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$13.74
- Trailing P/E Ratio -0.41
- Forward P/E Ratio -0.41
- P/E Growth -0.41
- Net Income $-15,961,658
Income Statement
Quarterly
Annual
Latest News of KTTA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo Finance
Pasithea Therapeutics Corp. shared positive results from the Phase 1 trial of PAS-004 in patients with advanced solid tumors, leading to an increase in stock price with high trading volume....
By Yahoo! Finance | 1 month ago
